Full Text View
Tabular View
No Study Results Posted
Related Studies
Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers
This study is currently recruiting participants.
Verified by Shaare Zedek Medical Center, April 2008
First Received: February 11, 2007   Last Updated: April 28, 2008   History of Changes
Sponsored by: Shaare Zedek Medical Center
Information provided by: Shaare Zedek Medical Center
ClinicalTrials.gov Identifier: NCT00434772
  Purpose

Thesis Infants of diabetic mothers are at high risk to develop hypoglycemia after birth.

After birth, glucose and ketone bodies are the main substrates of brain energy. Under normal condition, the adrenergic response seen immediately after birth suppresses insulin release and stimulates glucagon secretion which enhances gluconeogenesis and ketogenesis.

An inversion of the insulin/glucagon ratio is seen soon after birth as a normal, physiologic phenomenon. Consequently, a post delivery glucose nadir is reached between 30 to 90 minutes after birth, followed by a spontaneous recovery before 3-4 hours of age.

In infants of diabetic mothers, this inversion of the ratio is postponed and a more profound and sustained hypoglycemia is seen.

Early feeding is of great importance to diminish the severity and incidence of hypoglycemia. But, if despite an appropriate calorie intake, low levels of sugar are seen, an intravenous infusion of glucose should be commenced. In case that IV glucose is not effective or can't be supplied immediately, intramuscular glucagon is a therapeutic alternative. We hypothesize that a single intramuscular injection of glucagon together with the appropriate oral intake of nutrients is a safe and an effective alternative to the IV infusion of glucose alone in the treatment of hypoglycemia in term infants of diabetic mothers.

Methods Appropriately grown or large for date, term infants of insulin treated diabetic mothers, with no other known medical problems, are potential candidates for our study. Hypoglycemia will be defined as serum glucose level lower than 45 mg%. Infants of diabetic mothers will arrive to the nursery and immediately receive early feeding before 30 minutes of life. At that time, glucose will be checked. If glucose level is lower than 45 mg%, treatment with IV glucose or IM glucagon will be initiated. Glucose will be checked every hour for 4 hours and then every 3 hours (before each meal) for the next 20 hours. In case blood glucose level is lower than 20 mg% or falls below 45 mg% despite glucagon treatment, IV glucose will immediately be instituted.

Our aim is to check that IM Glucagon is as good as IV glucose in the treatment of hypoglycemia in infants of diabetic mothers. We will compare glucose levels after treatment with IV glucose and IM glucagon, the time till normalization of glucose and full feeding is achieved and the number of hospitalization days in both groups.


Condition Intervention Phase
Hypoglycemia
Drug: glucagon
Phase II

MedlinePlus related topics: Hypoglycemia
Drug Information available for: Glucagon
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment
Official Title: Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers

Further study details as provided by Shaare Zedek Medical Center:

Study Start Date: December 2007
  Eligibility

Ages Eligible for Study:   up to 48 Hours
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • asymptomatic hypoglycemia
  • infant of insulin treated diabetic mother
  • AGA or LGA
  • no other known medical problems

Exclusion Criteria:

  • concurrent medical problems
  • symptomatic hypoglycemia
  • glucose under 20 mg%
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00434772

Contacts
Contact: Cathy Hammerman, MD (=972-2) 666-6238 cathy@cc.huji.ac.il

Locations
Israel
Share Zedek Medical Center Recruiting
Jerusalem, Israel, 91031
Principal Investigator: Myriam Bisseliches, MD            
Sub-Investigator: Cathy Hammerman, MD            
Sponsors and Collaborators
Shaare Zedek Medical Center
Investigators
Principal Investigator: Bisseliches Myriam, MD Shaare Zedek Medical Center - Jerusalem - Israel
  More Information

No publications provided

Study ID Numbers: bisseliches-glucagon-ctil
Study First Received: February 11, 2007
Last Updated: April 28, 2008
ClinicalTrials.gov Identifier: NCT00434772     History of Changes
Health Authority: Israel: Ethics Commission

Study placed in the following topic categories:
Metabolic Diseases
Hormone Antagonists
Glucagon
Hormones, Hormone Substitutes, and Hormone Antagonists
Glucose Metabolism Disorders
Hypoglycemia
Hormones
Metabolic Disorder

Additional relevant MeSH terms:
Metabolic Diseases
Therapeutic Uses
Glucagon
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Glucose Metabolism Disorders
Hypoglycemia
Hormones
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 07, 2009